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Abstract
Introduction: Non-intensive care unit (ICU) cohorts have shown an association between inflammatory disturbances
and delirium, though these relationships have not been studied in critically ill patients. This study sought to
investigate the relationship between two inflammatory biomarkers, procalcitonin and C-reactive protein (CRP), and
duration of acute brain dysfunction in ventilated patients.
Methods: Patients enrolled in the Maximizing Efficacy of Targeted Sedation and Reducing Neurological
Dysfunction (MENDS) trial were assessed daily for delirium using the Confusion Assessment Method-ICU. Plasma
levels of procalcitonin and CRP were obtained within 24 hours of enrollment. Proportional odds logistic regression
was used to examine the association between procalcitonin and CRP separately with delirium/coma-free days,
adjusting for age, acute physiology score (APS) of the Acute Physiology And Chronic Health Evaluation (APACHE) II,
sedation group (dexmedetomidine vs. lorazepam), and sepsis. Secondary analyses examined the association of
these markers with other organ dysfunctions and 28-day survival.
Results: Eighty-seven patients were included in this analysis. The median age of the patients was 60 years with
APACHE II scores of 28; 68% had sepsis within 48 hours of admission. Higher levels of procalcitonin were
associated with fewer delirium/coma-free days [odds ratio (OR), 0.5; 95% confidence interval (CI), 0.3 to 1.0; P =
0.04], whereas higher CRP levels showed trends towards fewer delirium/coma-free days (OR, 0.6; 95% CI, 0.3 to 1.1;
P = 0.08). Similar relationships were found regardless of the presence of sepsis. No associations were found
between procalcitonin or CRP with 28-day survival (P = 0.40 and 0.16, respectively).
Conclusions: In our pilot study, high baseline inflammatory biomarkers predicted prolonged periods of acute brain
dysfunction, implicating inflammation as an important mechanism in the pathophysiology of delirium and coma
during critical illness, irrespective of whether patients had sepsis or not.
Introduction
Delirium, a form of acute brain dysfunction, is a leading
cause of morbidity and mortality in critically ill patients
[1-6]. Recent studies in this important area of critical
care have focused on elucidating risk factors of delirium
and developing strategies to reduce the prevalence and
duration of delirium, but little work has been done to
determine the mechanisms causing delirium in critically
ill patients [3,7-14].
Present theories regarding the pathogenesis of delir-
ium postulate a role for neurotransmitter imbalances
(dopamine, norepinephrine, acetylcholine and seroto-
nin), amino acids perturbations, oxidative stress, and
inflammation [15-18]. Studies have shown that higher
levels of C-reactive protein (CRP) and interleukin (IL)-6
are associated with a greater incidence of delirium in
postoperative hip surgery patients [19-21]. These bio-
markers may be general measures of complex inflamma-
tory processes that promote delirium, or they may
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ple, can incite the formation of reactive oxygen species,
causing disruption of the blood brain barrier and resul-
tant neuronal dysfunction, which may manifest as delir-
ium [19-21]. Procalcitonin has recently gained
popularity as an early marker for sepsis [22,23], though
n os t u d yt oo u rk n o w l e d g eh a se x a m i n e dt h er o l eo f
this or other inflammatory biomarkers in delirium in
critically ill mechanically ventilated patients.
The primary aim of our prospective cohort study was
to test the hypothesis that systemic inflammation, as
measured by the inflammatory biomarkers procalcitonin
and CRP, is associated with a longer duration of brain
dysfunction in mechanically ventilated patients.
Materials and methods
This prospective cohort study was nested within the
Maximizing Efficacy of Targeted Sedation and Reducing
Neurological Dysfunction (MENDS) [13] double-blind,
randomized controlled trial (Trial Registration: clinical-
trials.gov identifier: NCT00095251). This trial compared
dexmedetomidine and lorazepam for sedation during
acute mechanical ventilation, with both groups receiving
fentanyl for analgesia. The patient population has pre-
viously been described in detail: adult mechanically ven-
tilated, medical and surgical ICU patients from two
tertiary care centers were enrolled between August 2004
and April 2006, after excluding those in whom delirium
could not be reliably identified (for example, due to pre-
vious stroke, cerebral palsy, severe dementia, severe
hearing disabilities, or inability to understand English),
patients with active seizure disorder, Child-Pugh class B
or C cirrhosis, alcohol abuse, active myocardial ische-
mia, second- or third-degree heart block, and pregnancy
[13]. The institutional review board (IRB) at Vanderbilt
University, Nashville, Tennessee, approved this study
and informed consent was obtained from patients or
their authorized surrogates. Patients for whom surrogate
consent was obtained were re-consented once compe-
tent to provide informed consent.
At enrollment, we collected demographics and clinical
characteristics from the computerized medical record
and determined previous cognitive function through sur-
rogate interview using the validated Informant Question-
naire on Cognitive Decline in the Elderly (IQCODE) [24].
Blood samples for measurement of procalcitonin and
CRP were collected within 24 hours of enrollment and
centrifuged. Plasma was separated and stored at -80°C.
Procalcitonin was measured by Time Resolved Ampli-
fied Cryptate Emission (TRACE) Assay analysis on the
B.R.A.H.M.S. Kryptor
® Compact instrument, and CRP
was analyzed by the Roche Cobas Integra 800 analyzer
(Roche Diagnostic, Indianapolis, IN, USA). Both procal-
citonin and CRP have previously been shown to be
stable at room temperature and 4°C [25,26]. Addition-
ally, blood sampling technique (for example, arterial vs.
venous line) and repeated freezing/thawing cycles have
no significant influence on the procalcitonin or CRP
concentrations [25].
Delirium was assessed daily until hospital discharge or
for up to 12 days using the Confusion Assessment
Method for the Intensive Care Unit (CAM-ICU) [27,28].
Level of consciousness was measured with the Rich-
mond Agitation-Sedation Scale (RASS) [29,30]. Patients
were considered delirious if their RASS score was -3 or
greater (that is, -3 to +4) and they had a positive CAM-
ICU per the original validation studies of the CAM-ICU
[27,28]. Coma was defined as a RASS score of -4
(responsive to physical but not to verbal stimulus) or -5
(unresponsive to verbal and physical stimulus) [27,28].
Patients who were comatose were unable to be evalu-
ated for delirium, since delirium evaluation with the
CAM-ICU requires a patient to be responsive to voice.
For the purpose of this study, we chose delirium/
coma-free days (DCFD) as our outcome measure to
indicate the days during the 12-day study period that a
patient was alive and free of acute brain dysfunction
(delirium and coma); thus, this outcome reflects days
that a person has “normal” mental status as evaluated
by the CAM-ICU [13]. This outcome was chosen over
delirium days to avoid confounding by death, which
cuts short the duration of brain dysfunction if a patient
dies early, artificially improving neurologic outcomes.
Furthermore, delirium-free days (DFDs) was not chosen
as an outcome, since in DFDs even patients who are
comatose (as against normal) are considered “delirium-
free;” thus DFDs is not representative of better neurolo-
gical outcomes in populations where coma is common
[13]. Since DCFDs reflects not only brain dysfunction
but is also influenced by survival, we additionally
assessed the associations of procalcitonin and CRP with
other organ dysfunction-free days (for example, kidney-,
lung-, liver-, coagulation- and hemodynamic-dysfunction
free days) and 28-day survival. If the biomarkers are
associated with DCFDs primarily because of a relation-
ship with survival (rather than a brain-specific relation-
ship), then all organ dysfunction-free days should show
a similar association. The organ dysfunction definitions
were adapted from the Sequential Organ Failure Score
(SOFA) score cut-offs: kidney, Cr >2 mg/dL or urine
<400 cc/day; lung, PaO2/FiO2 <300 or SaO2/FiO2 <315
[31]; liver, total bilirubin >2 mg/dL; coagulation, platelet
count <100,000/mm
3; and hemodynamic, need for vaso-
pressor [32,33], consistent with definitions utilized in
published studies of organ dysfunction in critically ill
patients [34].
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Baseline demographic and clinical variables are pre-
sented using medians and interquartile ranges for con-
tinuous variables and proportions for categorical
variables. Because the distribution of DCFDs was heavily
skewed, we used proportional odds logistic regression to
determine the relationship between each biomarker
(baseline plasma procalcitonin or CRP, separately) and
our primary outcome of DCFDs, after adjustment for
age, APACHE II acute physiology score at enrollment,
treatment group (dexmedetomidine or lorazepam), and
sepsis. In our multivariable model, we wanted to adjust
for physiological changes that would confound the rela-
tionship between the inflammatory biomarkers and
delirium and also independently assess the role of age in
delirium. Since age is already incorporated into the
APACHE scoring system, this would have led to age
being accounted for twice in our models if we chose the
APACHE II as a covariate. Thus using the physiological
score from the APACHE served as a better covariate in
our model. In addition to the proportional odds model,
point estimates and 95% confidence intervals were cal-
culated using bootstrapped linear regression to estimate
t h ed i f f e r e n c ei nn u m b e ro fD C F D sb e t w e e np a t i e n t s
with values of procalcitonin or CRP at the 25
th vs. 75
th
percentiles of our population. To analyze the relation-
ships between the biomarkers and our secondary out-
comes of other organ dysfunction-free days and 28-day
survival, we used proportional odds logistic regression
and Cox proportional hazards regression, respectively,
adjusting for the same covariates. For Cox regression,
patients were censored at the time of last contact or at
study Day 28, whichever came first. Due to its skewed
distribution, procalcitonin concentrations were log
transformed prior to all analyses in order to provide bet-
ter model fits. Given that CRP and (in a more specific
way) procalcitonin are increased in sepsis, we evaluated
the hypothesis that the associations between these bio-
markers and outcomes could be influenced by the pre-
sence or absence of sepsis by including an interaction
term (inflammatory biomarker x sepsis) in each regres-
sion model. In all regression models, we also evaluated
the associations between biomarker concentrations and
outcomes for nonlinearity by including restricted cubic
splines. Nonlinear terms and interaction terms were
removed from each regression model if there was no
evidence of nonlinearity or an interaction, respectively
(that is, if P for nonlinearity or interaction >0.20). All
reported odds ratios (ORs) and 95% confidence intervals
(CIs) estimate the odds of more vs. fewer dysfunction-
free days among patients at the 75
th percentile of the
biomarker levels of our population vs. the 25
th percen-
tile (a more clinically relevant distinction than the tradi-
tional one-unit change in biomarker). We used R
version 2.9.1 for all statistical analyses (R Development
Core Team (2009); Vienna, Austria).
Results
Of the 103 patients enrolled in the MENDS study [13],
baseline procalcitonin and CRP data were available for
87 subjects who were included in the final analysis (16
patients had inadequate plasma samples for CRP and
procalcitonin measurements). Baseline characteristics of
the study population are listed in Table 1. The median
APACHE II and SOFA scores were high at baseline,
indicating this group of patients was critically ill; 68% of
the population was diagnosed with sepsis within 48
hours of admission to the ICU using the standard defi-
nition of suspected infection accompanied by at least
two SIRS (systemic inflammatory response syndrome)
criteria.
Associations of biomarkers with delirium/coma-free days
After adjusting for covariates, higher baseline procalcito-
nin levels were associated with fewer DCFDs, that is,
more brain dysfunction (OR, 0.5; 95% CI, 0.3 to 1.0; P =
0 . 0 4 ;T a b l e2a n dF i g u r e1 ) ,a n dh i g h e rb a s e l i n eC R P
levels showed a trend towards fewer DCFDs (OR, 0.6;
95% CI, 0.3 to 1.1; P =0 . 0 8 ;T a b l e2a n dF i g u r e2 ) .
Patients with a baseline procalcitonin level of 0.4 ng/ml
Table 1 Baseline demographics and clinical
characteristics
Variable* N =8 8
Age (years) 60 (49, 66)
Males 50%
APACHE II 28 (24, 32)
SOFA score 9 (8, 12)
Sepsis 68%
Brain dysfunction at enrollment
Coma 53%
Delirium 30%
Baseline RASS score
-4 or -5 52%
-3 or -2 27%
-1 to +1 21%
Baseline procalcitonin level (ng/ml) 1.53 (0.43, 6.74)
Baseline CRP level (ng/ml) 196 (107, 282)
Ever on vasoactive agents 55%
Duration of vasoactive agent use 1 (0, 3)
Days on mechanical ventilation 5.6 (3.2, 12.3)
ICU length of stay 9.2 (5.2, 17.4)
Hospital length of stay 15.6 (7.9, 23.5)
28-day mortality 26%
*Median (interquartile range) unless specified.
Abbreviations: APACHE II, Acute Physiological and Chronic Health Evaluation II;
CRP, C-reactive protein; RASS, Richmond Agitation-Sedation Scale; SOFA,
Sequential Organ Failure Score.
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th percentile value in our study population) had a
mean (95% CI) of 1.2 (0.1, 2.5) more days alive and free
of delirium and coma than those with a procalcitonin
level of 6.7 ng/ml (the 75
th percentile). Similarly,
patients with a baseline CRP level of 107 mg/L (the 25
th
percentile) had a mean (95% CI) of 1.0 (-0.25 to 2.3)
more day alive and free of delirium and coma than
those with a CRP level of 281.5 mg/L (the 75
th percen-
tile). Sepsis did not modify the relationships between
the biomarkers and DCFDs (that is, no interactions
were present); thus, patients with higher levels of procal-
citonin or CRP had fewer delirium/coma-free days irre-
spective of whether they had sepsis or not.
Associations of biomarkers with survival and other organ
dysfunction-free days
Baseline procalcitonin was nota s s o c i a t e dw i t hs u r v i v a l
(P = 0.40), nor was it associated with duration of lung
dysfunction (P = 0.95), liver dysfunction (P = 0.87), coa-
gulation dysfunction (P = 0.98) or kidney dysfunction
(0.23) (Table 2), suggesting that the association between
procalcitonin and DCFDs is a brain-specific association
rather than a result of an association with reduced sur-
vival. High baseline procalcitonin levels were associated
with fewer days free of hemodynamic dysfunction (P =
0.007); no interaction with sepsis was found (that is, this
association was present whether the patient had sepsis
or not) (Table 2).
CRP was not associated with survival (P = 0.16), dura-
tion of liver dysfunction (P = 0.74), coagulation dysfunc-
tion (P = 0.40), or hemodynamic dysfunction (P =0 . 1 6 ) .
Table 2 Inflammatory biomarkers and outcomes
Inflammatory Biomarker Odds
Ratio (95% Confidence
Intervals)*‡
Outcome Procalcitonin C-reactive
protein
Delirium/coma-free days 0.5 (0.3, 1.0) 0.6 (0.3, 1.1)
28-day survival
† 1.4 (0.7, 2.9) 1.7 (0.8, 3.4)
Kidney-dysfunction free days 0.7 (0.3, 1.3) —
Septic — 0.3 (0.1, 0.6)
Non-Septic — 2.6 (0.5, 12.4)
Lung-dysfunction free days 1.0 (0.5, 1.9) 0.4 (0.2, 0.8)
Liver-dysfunction free days 1.1 (0.5, 2.3) 0.9 (0.4, 1.9)
Coagulation-dysfunction free
days
1.0 (0.5, 1.9)
Septic — 1.1 (0.4, 2.6)
Non-Septic — 2.1 (0.3, 14.9)
Hemodynamic-dysfunction free
days
0.4 (0.2, 0.8) —
Septic — 0.6 (0.2, 1.4)
Non-Septic — 12.4 (0.7, 229.8)
Cardiac-dysfunction free days 0.6 (0.3, 1.3)
Septic — 0.7 (0.3, 1.5)
Non-Septic — 3.0 (0.5, 16.6)
*All reported ratios compare the odds or hazard of the outcome (for example,
more dysfunction-free days) among patients at the 75
th percentile of the
biomarker levels of our population to patients at the 25
th percentile. This is a
more clinically relevant comparison than a one-unit change in biomarker and
allows for some description of nonlinear association.
‡We assessed for interactions between the presence of sepsis and the
association of the biomarkers with each organ dysfunction outcome. A single
odds ratio is presented when sepsis did not affect the association of the
biomarker with the outcome. If a significant interaction with sepsis existed,
however, then two separate odds ratios are presented to show the different
associations between the biomarker and the organ dysfunction, depending on
the presence of sepsis.
†Hazard ratios are presented for 28-day survival.
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Figure 1 Association between baseline procalcitonin and
delirium/coma-free days. The dark line represents the point
estimates for the probability of the outcomes, while the dotted lines
represent the confidence intervals. The odds of having more
delirium/coma-free days (DCFDs) was significantly reduced with
increasing levels of procalcitonin (OR, 0.5; 95% CI, 0.3 to 1.0; P =
0.04). Thus, a patient with a baseline procalcitonin value of 6.7 ng/
ml (the 75th percentile value) would have half the odds of having
more DCFDs, as a patient with a baseline procalcitonin of 0.4 ng/ml
(the 25th percentile value).
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Figure 2 Association between baseline C-reactive protein (CRP)
and delirium/coma-free days. The dark line represents the point
estimates for the probability of the outcomes, while the dotted lines
represent the confidence intervals. The odds of having more
delirium/coma-free days (DCFDs) was reduced with increasing levels
of CRP (OR, 0.6; 95% CI, 0.4 to 1.1; P = 0.08). Thus, a patient with a
baseline CRP value of 281.5 mg/L (the 75th percentile value) would
have 0.6 times the odds of more DCFDs as a patient with a baseline
CRP of 107 mg/L (the 75th percentile value).
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probability of kidney and lung dysfunction-free days (P
= 0.005 and 0.008, respectively). The relationship
between CRP and kidney-dysfunction free days was sig-
nificantly modified by sepsis (interaction P =0 . 0 1 )
(Table 2). Thus, among the septic patients, a significant
association existed between CRP and kidney-dysfunction
free days, such that the highest CRP concentrations
were associated with a lower probability of kidney-dys-
function free days, after adjusting for covariates. How-
ever, among non-septic patients, this association was
not significant.
Discussion
To our knowledge this is the first study to show that
inflammation, as measured by procalcitonin and CRP, is
independently associated with acute brain dysfunction in
critically ill, mechanically ventilated patients. Specifically,
we found that high concentrations of procalcitonin were
associated with fewer days alive and free of delirium and
coma (meaning fewer days alive and free of brain dys-
function), and CRP showed a trend toward a similar
relationship, after adjusting for potential confounders.
No consistent association was found between these bio-
markers and other organ dysfunctions (that is, some
were related but most, along with survival, were not),
indicating the associations with duration of brain dys-
function are likely organ-specific.
The findings of our study suggest inflammation may
be one important contributor to acute brain dysfunction
(delirium and coma) in ICU patients, irrespective of the
presence or absence of sepsis or the influence of inflam-
mation on survival and other organ dysfunctions
[35-38]. Inflammatory mediators produced during criti-
cal illness (for example, tumor necrosis factor-a,i n t e r -
leukin-1) initiate a systemic cascade of endothelial
damage, thrombin formation, and microvascular com-
promise [39]. Studies in animal models have revealed
that these inflammatory mediators cross the blood-brain
barrier [40], increase vascular permeability in the brain
[41], and result in changes on electroencephalography
(EEG) that are consistent with those seen in patients
with delirium [42,43]. Inflammation may also incite
brain dysfunction by constricting cerebral vasculature
through activation of a1-adrenoceptors [44] or by inter-
fering with neurotransmitter synthesis and neurotrans-
mission [15].
There is debate within the literature whether procalcito-
nin is a specific marker of infection, though receiver oper-
ating curve (ROC) characteristics in some studies suggest
that the performance of procalcitonin as a marker of sepsis
is superior to that of CRP [22,23]. CRP on the other hand,
is thought to be a general marker of systemic inflamma-
tion, of which infection is one common cause [45]. As we
found an association between procalcitonin levels and
DCFDs in patients with sepsis and in those without sepsis,
our results suggest that inflammation due to sepsis was
not the sole driver of procalcitonin’s association with
DCFDs. Additionally the trend shown with CRP supports
our hypothesis that inflammation of either infectious or
non-infectious etiologies is associated with ICU delirium
and coma. Larger cohort studies are needed to elucidate
the contribution of specific causes of inflammation to
acute brain dysfunction in the ICU.
There are several strengths and limitations in our
study. First, this pilot investigation, which evaluated 87
patients, may lack adequate statistical power to detect
some clinically important associations. Furthermore, the
limited number of patients prevented us from studying
potential differences in various subgroups such as surgi-
cal versus medical ICU patients; for example, some data
suggest that post-surgical patients have elevated levels of
procalcitonin dependent o nt h en a t u r ea n de x t e n to f
surgery [46,47]. Despite thesel i m i t a t i o n s ,w ew e r ea b l e
to show associations between procalcitonin and CRP
with DCFDs, providing a basis for studying the role of
inflammation in delirium and coma in the ICU. Second,
because we studied only baseline procalcitonin and CRP
levels, we were unable to assess whether changes in
these inflammatory markers over time are associated
with the resolution or persistence of brain dysfunction.
Third, because of our small sample size, only a limited
number of covariates could be included in our regres-
sion models; the inclusion of additional potential con-
founders would have increased the possibility of
obtaining unreliable results due to overfitting. We did,
however, adjust for sepsis, which represents a major risk
factor. Furthermore, our results are consistent with stu-
dies that have shown an association of CRP with delir-
ium in non-ICU cohorts [19-21], delirium following
stroke [48] and sepsis [49], and delirium in one small
study of 32 ICU patients, which did not adjust for con-
founders [50]. Additionally, we found that among septic
patients, higher baseline CRP levels were associated with
a greater duration of renal dysfunction, which is in con-
cordance with a previous study by Lobo et al. [51] that
showed that increased admission CRP was proportional
to days of renal support therapy. Fourth, our chosen
outcome of delirium/coma-free days (representing the
days alive without delirium or coma) can be influenced
by death, which in turn may be dependent on other
organ dysfunctions. We assessed the role of both procal-
c i t o n i na n dC R Pi nn o n - b r a i no r g a nd y s f u n c t i o n sa n d
survival and found little evidence that the observed asso-
ciations between the biomarkers and delirium/coma-free
days were driven by a relationship with survival. In fact,
there were no associations between the biomarkers and
survival in our study. Finally, we assessed patients only
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ICU negative were considered to be “free of brain dys-
function” for the entire day. Given that delirium is a
fluctuating state of mental status, it is possible that
some patients developed delirium later in the day and
were missed in our study.
Conclusions
In this pilot study, inflammation, as measured by high
procalcitonin and CRP levels at admission, was asso-
ciated with fewer days alive and free of acute brain dys-
function in critically ill patients, suggesting that
inflammation plays an important role in delirium and
coma in the ICU. Future studies are needed to elucidate
further the inflammatory mechanisms of delirium and
coma during critical illness.
Key messages
￿ Delirium is a highly prevalent organ dysfunction in
the critically ill with associated morbidity and
mortality.
￿ Present theories regarding the pathogenesis of
delirium postulate a role for neurotransmitter imbal-
ances (dopamine, norepinephrine, acetylcholine and
serotonin), amino acids perturbations, oxidative
stress, and inflammation.
￿ In this prospective cohort study of critically ill
patients, increasing levels of procalcitonin at admis-
sion were associated with longer duration of brain
dysfunction. C-reactive protein showed similar
trends.
￿ The association between increasing biomarkers and
worse brain dysfunction was independent of sepsis;
thus inflammatory perturbations of either infective
o rn o n - i n f e c t i v ee t i o l o g yw e r eb o t ha s s o c i a t e dw i t h
delirium.
￿ There was not a consistent association between
procalcitonin or C-reactive protein and other organ
dysfunctions or death implying that inflammation
may have a bigger impact on the brain than just glo-
bal organ dysfunction.
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